![Jonathan Charles Alexander Skipper](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan Charles Alexander Skipper
Director/Board Member at Cancer Vaccine Acceleration Co. LLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michel Detheux | M | 57 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 13 years |
José Fernando Perez | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | 18 years |
Edward A. McDermott | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Indrani Majumder | F | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Tim van Hauwermeiren | M | 52 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 years |
Ann Rhoads | F | 58 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 4 years |
Pedro Lins Palmeira Filho | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Míriam Albagli de Almeida | F | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Victor Hugo Gomes Odorcyk | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Sonia Mansoldo Dainesi | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | 8 years |
Barbara S. Jones | F | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Jedd D. Wolchok | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | 1 years |
Chi Van Dang | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Nancy E. Davidson | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Alexandra Johnson | F | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Pierre Coulie | M | - |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
Nicolas Killen | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | 1 years |
Vincenzo Bronte | M | - |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
Stephen Charles O’Sullivan | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Robert Kramer | M | 72 |
iOX Therapeutics Ltd.
![]() iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | - |
Jovelino de Carvalho Mineiro | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
John Gordan | M | 78 |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Ian Walters | M | 57 |
iOX Therapeutics Ltd.
![]() iOX Therapeutics Ltd. BiotechnologyHealth Technology iOX Therapeutics Ltd. provides cancer therapeutics services. The company was founded by Vincenzo Cerundolo in February 2015 and is headquartered in London, the United Kingdom. | - |
Ian Leitch | M | 60 | 13 years | |
Stefano Crosignani | M | - |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
José Barbosa Mello | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Robert L. Strausberg | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
John L. Notter | M | - |
Ludwig Institute for Cancer Research Ltd.
![]() Ludwig Institute for Cancer Research Ltd. Medical/Nursing ServicesHealth Services Ludwig Institute For Cancer Research Ltd. is non-profit organization engages in the prevention and control of cancer through researches, integrated laboratory and clinical trials. The firm operates in the areas of cell biology, genomics, immunology, neuroscience, signaling, stem cells, therapeutic, tumor biology, brain and breast cancer, immunotherapy, and melanoma. The company was founded by Daniel K. Ludwig in 1971 and is headquartered in New York, NY. | - |
Michael Gerometta | M | - | 16 years | |
Priyanka Belawat | M | 45 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 years |
Al Gray | M | - |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | - |
Matthew Call | M | 51 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 5 years |
Christiana Goh Bardon | M | 53 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 years |
Emílio Alves Odebrecht | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
David Hallal | M | 56 |
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | 6 years |
Luiz Travassos | M | - |
Recepta Biopharma SA
![]() Recepta Biopharma SA BiotechnologyHealth Technology Recepta Biopharma SA researches and develops drugs for cancer treatment. It is a biotechnology company which is engaged in the research, development, production and marketing of human antibodies for the diagnosis and treatment of human cancer. The company was founded in 2006 and is headquartered in Sao Paulo, Brazil. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Natalie Korchev | F | - | 10 years | |
Susan Madden | F | - | - | |
Carlo Montagner | M | 56 | 3 years | |
John Wilcox Stocker | M | 79 | 12 years | |
Alexander Szabo | M | - | 2 years | |
Errol Malta | M | - | 3 years | |
Mark Sullivan | M | - | 3 years | |
Angus Tester | M | - | 7 years | |
Natalya Jurcheshin | F | - | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
Brazil | 11 | 24.44% |
Australia | 11 | 24.44% |
Belgium | 11 | 24.44% |
United States | 10 | 22.22% |
United Kingdom | 2 | 4.44% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jonathan Charles Alexander Skipper
- Personal Network